Trial
NCT00640978
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
Novartis; OSI Pharmaceuticals
Condition
Pancreatic Cancer
Intervention
RAD001
Why stopped
Significant Adverse Effects - Futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-01